亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)

吉西他滨 医学 胰腺癌 肿瘤科 内科学 化疗 人口 外科 癌症 胃肠病学 环境卫生
作者
Katsuhiko Uesaka,Narikazu Boku,Akira Fukutomi,Yukiyasu Okamura,Masaru Konishi,Ippei Matsumoto,Yuji Kaneoka,Yasuhiro Shimizu,Shoji Nakamori,Hirohiko Sakamoto,Soichiro Morinaga,Osamu Kainuma,Koji Imai,Naohiro Sata,Shoichi Hishinuma,Hitoshi Ojima,Ryuzo Yamaguchi,Satoshi Hirano,Takeshi Sudo,Yasuo Ohashi
出处
期刊:The Lancet [Elsevier BV]
卷期号:388 (10041): 248-257 被引量:1148
标识
DOI:10.1016/s0140-6736(16)30583-9
摘要

Although adjuvant chemotherapy with gemcitabine is standard care for resected pancreatic cancer, S-1 has shown non-inferiority to gemcitabine for advanced disease. We aimed to investigate the non-inferiority of S-1 to gemcitabine as adjuvant chemotherapy for pancreatic cancer in terms of overall survival.We did a randomised, open-label, multicentre, non-inferiority phase 3 trial undertaken at 33 hospitals in Japan. Patients who had histologically proven invasive ductal carcinoma of the pancreas, pathologically documented stage I-III, and no local residual or microscopic residual tumour, and were aged 20 years or older were eligible. Patients with resected pancreatic cancer were randomly assigned (in a 1:1 ratio) to receive gemcitabine (1000 mg/m(2), intravenously administered on days 1, 8, and 15, every 4 weeks [one cycle], for up to six cycles) or S-1 (40 mg, 50 mg, or 60 mg according to body-surface area, orally administered twice a day for 28 days followed by a 14 day rest, every 6 weeks [one cycle], for up to four cycles) at the data centre by a modified minimisation method, balancing residual tumour status, nodal status, and institutions. The primary outcome was overall survival in the two treatment groups, assessed in the per-protocol population, excluding ineligible patients and those not receiving the allocated treatment. The protocol prespecified that the superiority of S-1 with respect to overall survival was also to be assessed in the per-protocol population by a log-rank test, if the non-inferiority of S-1 was verified. We estimated overall and relapse-free survival using the Kaplan-Meier methods, and assessed non-inferiority of S-1 to gemcitabine using the Cox proportional hazard model. The expected hazard ratio (HR) for mortality was 0.87 with a non-inferiority margin of 1.25 (power 80%; one-sided type I error 2.5%). This trial is registered at UMIN CTR (UMIN000000655).385 patients were randomly assigned to treatment between April 11, 2007, and June 29, 2010 (193 to the gemcitabine group and 192 to the S-1 group). Of these, three were exlcuded because of ineligibility and five did not receive chemotherapy. The per-protocol population therefore consisted of 190 patients in the gemcitabine group and 187 patients in the S-1 group. On Sept 15, 2012, following the recommendation from the independent data and safety monitoring committee, this study was discontinued because the prespecified criteria for early discontinuation were met at the interim analysis for efficacy, when all the protocol treatments had been finished. Analysis with the follow-up data on Jan 15, 2016, showed HR of mortality was 0.57 (95% CI 0.44-0.72, pnon-inferiority<0.0001, p<0.0001 for superiority), associated with 5-year overall survival of 24.4% (18.6-30.8) in the gemcitabine group and 44.1% (36.9-51.1) in the S-1 group. Grade 3 or 4 leucopenia, neutropenia, aspartate aminotransferase, and alanine aminotransferase were observed more frequently in the gemcitabine group, whereas stomatitis and diarrhoea were more frequently experienced in the S-1 group.Adjuvant chemotherapy with S-1 can be a new standard care for resected pancreatic cancer in Japanese patients. These results should be assessed in non-Asian patients.Pharma Valley Center, Shizuoka Industrial Foundation, Taiho Pharmaceutical.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
饱满飞扬完成签到,获得积分10
1秒前
1秒前
鲜艳的乐珍完成签到,获得积分10
2秒前
3秒前
4秒前
chunI发布了新的文献求助10
7秒前
我是老大的应助被肉包子采纳,获得10
9秒前
10秒前
fuyuting完成签到 ,获得积分10
12秒前
桐夜完成签到 ,获得积分10
13秒前
15秒前
17秒前
19秒前
Foloydon发布了新的文献求助10
20秒前
22秒前
斯文败类的应助被Foloydon采纳,获得10
24秒前
哈哈发布了新的文献求助10
25秒前
26秒前
28秒前
Drunk发布了新的文献求助10
32秒前
干净的中心完成签到,获得积分10
37秒前
挖掘机完成签到,获得积分10
40秒前
42秒前
44秒前
yann完成签到,获得积分10
45秒前
陌宸希完成签到 ,获得积分10
47秒前
学术雷锋发布了新的文献求助10
49秒前
EllenLawliet发布了新的文献求助10
52秒前
风中柚子完成签到 ,获得积分10
53秒前
54秒前
Ww完成签到,获得积分10
56秒前
fangmu完成签到,获得积分10
58秒前
无限的寡妇完成签到,获得积分10
58秒前
1分钟前
深情安青的应助被Gary采纳,获得10
1分钟前
1分钟前
1分钟前
Foloydon完成签到,获得积分10
1分钟前
LX有理想发布了新的文献求助10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158598
求助须知:如何正确求助?哪些是违规求助? 9554358
关于积分的说明 21719087
捐赠科研通 7748128
什么是DOI,文献DOI怎么找? 3427032
关于科研通互助平台的介绍 2551902
邀请新用户注册赠送积分活动 2471277